Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tarceva Pancreatic Cancer Survival Benefit Is Small But Clinically Meaningful, Committee Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Tarceva (erlotinib) survival difference of two weeks to one month, depending on the analysis, is statistically persuasive, FDA’s Oncologic Drugs Advisory Committee says at Sept. 13 meeting.

You may also be interested in...

From Avastin To Zevalin: ODAC’s Most Memorable Moments

The current and former leaders of FDA’s Oncologic Drugs Advisory Committee recount their most memorable moments of service on the panel.

Roche's Xeloda Shows Significant Survival Benefit In Pancreatic Cancer

Combo therapy of Xeloda plus gemcitabine shows median survival of 7.4 months versus six months with Gemzar alone.

FDA Approves Tarceva For Pancreatic Cancer

Supplemental NDA approval for Genentech/OSI’s erlotinib, previously approved for lung cancer, follows advisory committee recommendation.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts